rHIgM12B7

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug NamerHIgM12B7
Drug Alias NamesHIgM12B7-DC-crosslinking recombinant human monoclonal antibody (Mayo Clinic)
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionProgrammed death-ligand 2 modulators
TargetsProgrammed death-ligand 2
Therapy Area/IndicationsInflammationNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesMayo Clinic
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesMayo Clinic
Active IndicationsN/A
Inactive IndicationsInflammationNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A